just the Preview – Dr Pepper Snapple Group’s Q4 and FY

Dr Pepper Snapple Group (DPSG) is set to report its final quarter and full-year results tomorrow (17 February). Here, just-drinks takes a look at the highs and lows for DPSG in the three months to the end of December.

• At the beginning of October, DPSG completed the licensing of certain brands to The Coca-Cola Co following the latter’s takeover of the North America operations of Coca-Cola Enterprises. Under the new licensing agreements, Coca-Cola will distribute Dr Pepper in the US and Canada Dry in the north-east US where they were formerly distributed by CCE.
• In the same month, the Texas-based soft drinks firm confirmed to just-drinks that it expects sales of Snapple drinks to grow at double-digit rates this year, driven by a “complete re-staging” of the business. DPSG said it expects full-year sales growth of about 10% to 14% for its Snapple portfolio, and comes despite the firm recording a drop in first-half profits in July.
• In November, DPSG launched Limited Edition Pomegranate 7UP Antioxidant. The drink is a blend of pomegranate flavour and the original lemon-lime soft drink, and is available in both regular and diet.
• A month later, the company announced a private offer to exchange up to US$600m of its outstanding 6.82% senior notes due in 2018. The firm also announced its offer to purchase up to $600m in aggregate principal amount of its 2018 notes for cash only.
• Also in December, DPSG promoted two of its executive leadership team to the level of executive VP. The company appointed David Thomas as EVP of research & development, and Tina Barry as EVP of corporate affairs.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

Sign up